Alfred Zippelius

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8106951/publications.pdf Version: 2024-02-01



DED 7IDDE

#	Article	IF	CITATIONS
1	Magnesium sensing via LFA-1 regulates CD8+ TÂcell effector function. Cell, 2022, 185, 585-602.e29.	28.9	83
2	Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer. Frontiers in Cell and Developmental Biology, 2022, 10, 828916.	3.7	16
3	Effects of COVID-19 Lockdown on Melanoma Diagnosis in Switzerland: Increased Tumor Thickness in Elderly Females and Shift towards Stage IV Melanoma during Lockdown. Cancers, 2022, 14, 2360.	3.7	10
4	Validation of Pretreatment Prognostic Factors and Prognostic Staging Systems for Small Cell Lung Cancer in a Real-World Data Set. Cancers, 2022, 14, 2625.	3.7	2
5	Abstract 4149: Knock-down of Neuropilin-1 by locked nucleic acid antisense oligonucleotides facilitates cancer immune control. Cancer Research, 2022, 82, 4149-4149.	0.9	0
6	NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity. Science Translational Medicine, 2022, 14, .	12.4	29
7	iMATCH: an integrated modular assembly system for therapeutic combination high-capacity adenovirus gene therapy. Molecular Therapy - Methods and Clinical Development, 2021, 20, 572-586.	4.1	21
8	Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 TÂcell attack. Cell Reports Medicine, 2021, 2, 100209.	6.5	16
9	Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity. Frontiers in Oncology, 2021, 11, 644608.	2.8	19
10	Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies. Frontiers in Immunology, 2021, 12, 674565.	4.8	28
11	Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients – evaluation of outcome and prognostic factors: A retrospective multicenter study. PLoS ONE, 2021, 16, e0253601.	2.5	13
12	Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature, 2021, 594, 566-571.	27.8	139
13	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nature Medicine, 2021, 27, 1250-1261.	30.7	159
14	SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial. Journal of Clinical Oncology, 2021, 39, 2872-2880.	1.6	183
15	Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in nonâ€small cell lung cancer. Journal of Pathology, 2020, 250, 19-29.	4.5	92
16	Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 541-551.	7.1	66
17	A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression. Cancer Immunology, Immunotherapy, 2020, 69, 57-67.	4.2	6
18	Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer		60

immunotherapy. , 2020, 8, e001222.

60

#	Article	IF	CITATIONS
19	Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. Nature Immunology, 2020, 21, 1540-1551.	14.5	252
20	Hyperglycemia Enhances Cancer Immune Evasion by Inducing Alternative Macrophage Polarization through Increased O-GlcNAcylation. Cancer Immunology Research, 2020, 8, 1262-1272.	3.4	32
21	Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. , 2020, 8, e000238.		35
22	CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature Immunology, 2020, 21, 298-308.	14.5	326
23	PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. Cancer Immunology, Immunotherapy, 2020, 69, 1505-1517.	4.2	58
24	SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial Journal of Clinical Oncology, 2020, 38, 9016-9016.	1.6	27
25	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 485-495.	2.8	3
26	Humanized Monoclonal Antibody Blocking Carbonic Anhydrase 12 Enzymatic Activity Leads to Reduced Tumor Growth <i>In Vitro</i> . Anticancer Research, 2019, 39, 4117-4128.	1.1	14
27	Therapeutic Targeting of Golgi Phosphoprotein 2 (GOLPH2) with Armed Antibodies: A Preclinical Study of Anti-GOLPH2 Antibody Drug Conjugates in Lung and Colorectal Cancer Models of Patient Derived Xenografts (PDX). Targeted Oncology, 2019, 14, 577-590.	3.6	4
28	Tumor-derived TGF-β inhibits mitochondrial respiration to suppress IFN-γ production by human CD4 ⁺ T cells. Science Signaling, 2019, 12, .	3.6	61
29	GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. Cell Reports, 2019, 28, 3367-3380.e8.	6.4	37
30	Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle. Nature Immunology, 2019, 20, 206-217.	14.5	51
31	A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. , 2019, 7, 16.		68
32	RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types. Cell Reports, 2019, 26, 1627-1640.e7.	6.4	590
33	Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy. Science Translational Medicine, 2019, 11, .	12.4	178
34	MALDI Detection of Exosomes: A Potential Tool for Cancer Studies. CheM, 2019, 5, 1318-1336.	11.7	42
35	Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1043.	7.1	266
36	Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. Cancer Immunology Research, 2019, 7, 707-718.	3.4	94

#	Article	IF	CITATIONS
37	Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity. , 2019, 7, 67.		43
38	Cancer immunology, inflammation, and tolerance: an introduction. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 405-406.	2.8	2
39	A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clinical Cancer Research, 2019, 25, 3026-3034.	7.0	29
40	Phase lb evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. , 2019, 7, 38.		121
41	A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2019, 68, 799-812.	4.2	115
42	Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study. Melanoma Research, 2019, 29, 65-69.	1.2	27
43	Tumor mutational burden assessed by a targeted NGS assay to predict clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer Journal of Clinical Oncology, 2019, 37, e14266-e14266.	1.6	1
44	Toxicity associated with PD-1 blockade after allogeneic haematopoietic cell transplantation. Swiss Medical Weekly, 2019, 149, w20150.	1.6	3
45	Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort Study. Swiss Medical Weekly, 2019, 149, w20078.	1.6	11
46	Arenavirus-based vector platform for massive tumor self-antigen-specific CD8 T cell immunity Journal of Clinical Oncology, 2019, 37, e14297-e14297.	1.6	0
47	Blocking LILRB and KIR receptors by B57 open conformers induces potent antitumor activity and acts synergistically with checkpoint blockade inhibition Journal of Clinical Oncology, 2019, 37, e14137-e14137.	1.6	0
48	The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Cancer Immunology, Immunotherapy, 2018, 67, 815-824.	4.2	42
49	Targeting Insulin-Like Growth Factor-I and Extracellular Matrix Interactions in Melanoma Progression. Scientific Reports, 2018, 8, 583.	3.3	16
50	The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncolmmunology, 2018, 7, e1386362.	4.6	62
51	Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer. Breast Cancer Research, 2018, 20, 141.	5.0	20
52	Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. Immunity, 2018, 49, 1148-1161.e7.	14.3	639
53	Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab. , 2018, 6, 85.		19
54	Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. , 2018, 6, 40.		110

#	Article	IF	CITATIONS
55	Current and future developments of immunotherapy in lung cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 122-131.	0.5	1
56	A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nature Medicine, 2018, 24, 994-1004.	30.7	783
57	Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. Journal of Clinical Investigation, 2018, 128, 4912-4923.	8.2	214
58	SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial Journal of Clinical Oncology, 2018, 36, TPS8584-TPS8584.	1.6	3
59	Immunotherapy in head and neck cancer – scientific rationale, current treatment options and future directions. Swiss Medical Weekly, 2018, 148, w14625.	1.6	23
60	Tumor mutational burden assessed by a targeted NGS assay to predict benefit from immune checkpoint inhibitors in non-small cell lung cancer Journal of Clinical Oncology, 2018, 36, e15075-e15075.	1.6	0
61	Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy. Nature Communications, 2017, 8, 15327.	12.8	61
62	P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC. Journal of Thoracic Oncology, 2017, 12, S1333-S1334.	1.1	1
63	PUB041 HGF, VEGFA and ANGPT2 Predict Clinical Benefit from Bevacizumab and Chemotherapy in Patients with Advanced NSCLC (SAKK19/09). Journal of Thoracic Oncology, 2017, 12, S1471.	1.1	0
64	P1.07-041 Validation of Prognostic Scores in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S721-S722.	1.1	0
65	Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non–Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. Clinical Lung Cancer, 2017, 18, 303-309.	2.6	13
66	Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade. , 2017, 5, 46.		64
67	Immune response and adverse events to influenza vaccine in cancer patients undergoing PD-1 blockade Journal of Clinical Oncology, 2017, 35, e14523-e14523.	1.6	6
68	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. Oncotarget, 2017, 8, 69204-69218.	1.8	21
69	Agonistic anti-CD40 therapy synergizes with LAG-3-blocking antibodies. International Journal of Clinical Pharmacology and Therapeutics, 2017, 55, 692-694.	0.6	1
70	Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort. Journal of Cancer, 2016, 7, 2110-2116.	2.5	23
71	Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine. PLoS ONE, 2016, 11, e0160807.	2.5	15
72	Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study. , 2016, 4, 13.		162

#	Article	IF	CITATIONS
73	Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. Cancer Immunology Research, 2016, 4, 744-754.	3.4	131
74	Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. , 2016, 4, 47.		27
75	Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunology, Immunotherapy, 2016, 65, 1-11.	4.2	34
76	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. Oncolmmunology, 2016, 5, e1100789.	4.6	45
77	Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncolmmunology, 2016, 5, e1062969.	4.6	27
78	SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial Journal of Clinical Oncology, 2016, 34, TPS8573-TPS8573.	1.6	1
79	Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience. Journal of Cancer, 2015, 6, 1148-1154.	2.5	26
80	Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs. Frontiers in Immunology, 2015, 6, 501.	4.8	33
81	Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment. Cancer Immunology Research, 2015, 3, 236-244.	3.4	117
82	Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma. Lung Cancer, 2015, 88, 9-15.	2.0	16
83	Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. Journal of the National Cancer Institute, 2015, 107, djv171-djv171.	6.3	78
84	Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clinical Lung Cancer, 2015, 16, 358-365.	2.6	14
85	Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. , 2015, 3, 11.		274
86	Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunology Research, 2015, 3, 1344-1355.	3.4	285
87	Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncology, The, 2015, 16, 1651-1658.	10.7	170
88	Vemurafenib-Induced Radiation Recall Dermatitis: Case Report and Review of the Literature. Dermatology, 2015, 230, 1-4.	2.1	23
89	Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet, The, 2015, 386, 1049-1056.	13.7	316
90	Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Science Translational Medicine, 2015, 7, 315ra188.	12.4	261

#	Article	IF	CITATIONS
91	Cancer immunology – development of novel anti-cancer therapies. Swiss Medical Weekly, 2015, 145, w14066.	1.6	18
92	Stage dependent increase of CCL2 and CCL5 in peripheral blood of colorectal cancer patients Journal of Clinical Oncology, 2015, 33, e22111-e22111.	1.6	0
93	Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. BMC Cancer, 2014, 14, 748.	2.6	101
94	Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity. Oncolmmunology, 2014, 3, e954460.	4.6	19
95	Follow-up in non-small-cell lung cancer. Memo - Magazine of European Medical Oncology, 2014, 7, 97-101.	0.5	0
96	Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells. Cancer Immunology Research, 2014, 2, 741-755.	3.4	134
97	The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunology, Immunotherapy, 2014, 63, 925-938.	4.2	60
98	Cetuximab in Metastatic Squamous Cell Cancer of the Skin: A Swiss Case Series. Dermatology, 2014, 229, 97-101.	2.1	18
99	Carboplatin and Paclitaxel Plus ASA404 as First-Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer: A Multicenter Single Arm Phase II Trial (SAKK 15/08). Clinical Lung Cancer, 2013, 14, 34-39.	2.6	19
100	Neoadjuvant chemotherapy with or without preoperative irradiation in stage IIIA/N2 non-small cell lung cancer (NSCLC): A randomized phase III trial by the Swiss Group for Clinical Cancer Research (SAKK trial 16/00) Journal of Clinical Oncology, 2013, 31, 7503-7503.	1.6	9
101	Messenger RNA vaccination and B-cell responses in NSCLC patients Journal of Clinical Oncology, 2012, 30, 2573-2573.	1.6	9
102	Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunology, Immunotherapy, 2009, 58, 325-338.	4.2	27
103	Four Functionally Distinct Populations of Human Effector-Memory CD8+ T Lymphocytes. Journal of Immunology, 2007, 178, 4112-4119.	0.8	347
104	FDG PET/CT Imaging of a Gastric Fistula. Clinical Nuclear Medicine, 2007, 32, 336-337.	1.3	2
105	Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin. Journal of Immunology, 2007, 178, 320-329.	0.8	309
106	NY-ESO-1 protein expression in primary breast carcinoma and metastases—correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration. International Journal of Cancer, 2007, 120, 2411-2417.	5.1	65
107	A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer. Journal of Immunological Methods, 2007, 323, 180-193.	1.4	14
108	Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunology, Immunotherapy, 2006, 56, 249-258.	4.2	17

#	Article	IF	CITATIONS
109	Ex Vivo Characterization of Allo-MHC-Restricted T Cells Specific for a Single MHC-Peptide Complex. Journal of Immunology, 2006, 176, 2330-2336.	0.8	22
110	Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients. Journal of Immunology, 2006, 177, 8212-8218.	0.8	24
111	High frequencies of functionally impaired cytokeratin 18-specific CD8+ T cells in healthy HLA-A2+ donors. European Journal of Immunology, 2005, 35, 2876-2885.	2.9	27
112	Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance. Cancer Research, 2004, 64, 2865-2873.	0.9	351
113	Human Thymus Exports Naive CD8 T Cells That Can Home to Nonlymphoid Tissues. Journal of Immunology, 2004, 172, 2773-2777.	0.8	19
114	High Frequency of Functionally Active Melan-A–Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient Melanoma. Cancer Research, 2004, 64, 6319-6326.	0.9	60
115	Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning. Cancer Immunology, Immunotherapy, 2004, 53, 144-147.	4.2	48
116	α3 Domain Mutants of Peptide/MHC Class I Multimers Allow the Selective Isolation of High Avidity Tumor-Reactive CD8 T Cells. Journal of Immunology, 2003, 171, 1844-1849.	0.8	65
117	Prevalent Role of TCR α-Chain in the Selection of the Preimmune Repertoire Specific for a Human Tumor-Associated Self-Antigen. Journal of Immunology, 2003, 170, 5103-5109.	0.8	76
118	Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood, 2003, 102, 1779-1787.	1.4	167
119	Endotoxin and asthma. New England Journal of Medicine, 2003, 348, 171-4; author reply 171-4.	27.0	1
120	Activation of human melanoma reactive CD8+ T cells by vaccination with an immunogenic peptide analog derived from Melan-A/melanoma antigen recognized by T cells-1. Clinical Cancer Research, 2003, 9, 669-77.	7.0	37
121	Thymic Selection Generates a Large T Cell Pool Recognizing a Self-Peptide in Humans. Journal of Experimental Medicine, 2002, 195, 485-494.	8.5	136
122	Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer+ CD8+ T Cells in Humans. Journal of Experimental Medicine, 2002, 196, 207-216.	8.5	90
123	Adapted NOD/SCID model supports development of phenotypically and functionally mature T cells from human umbilical cord blood CD34+ cells. Blood, 2002, 99, 1620-1626.	1.4	66
124	Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunological Reviews, 2002, 188, 81-96.	6.0	146
125	Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Research, 2002, 62, 251-61.	0.9	55
126	Ex Vivo IFN-Î ³ Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases. Journal of Immunology, 2001, 166, 7634-7640.	0.8	135

#	Article	IF	CITATIONS
127	Steatosis Hepatis in Celiac Disease. Journal of Hepatology, 1999, 30, 531.	3.7	15